Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Guided Therapeutics (GTHP) Non-Current Debt (2016 - 2025)

Guided Therapeutics (GTHP) has disclosed Non-Current Debt for 12 consecutive years, with $23000.0 as the latest value for Q4 2025.

  • Quarterly Non-Current Debt fell 51.06% to $23000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $23000.0 through Dec 2025, down 51.06% year-over-year, with the annual reading at $23000.0 for FY2025, 51.06% down from the prior year.
  • Non-Current Debt hit $23000.0 in Q4 2025 for Guided Therapeutics, down from $29000.0 in the prior quarter.
  • In the past five years, Non-Current Debt ranged from a high of $586000.0 in Q3 2021 to a low of $6000.0 in Q1 2021.
  • Historically, Non-Current Debt has averaged $159500.0 across 4 years, with a median of $50000.0 in 2024.
  • Biggest five-year swings in Non-Current Debt: plummeted 98.96% in 2021 and later surged 9366.67% in 2022.
  • Year by year, Non-Current Debt stood at $22000.0 in 2021, then soared by 277.27% to $83000.0 in 2022, then tumbled by 43.37% to $47000.0 in 2024, then crashed by 51.06% to $23000.0 in 2025.
  • Business Quant data shows Non-Current Debt for GTHP at $23000.0 in Q4 2025, $29000.0 in Q3 2025, and $35000.0 in Q2 2025.